<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="256">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05256134</url>
  </required_header>
  <id_info>
    <org_study_id>WN42444</org_study_id>
    <secondary_id>2021-001184-25</secondary_id>
    <nct_id>NCT05256134</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)</brief_title>
  <acronym>SKYLINE</acronym>
  <official_title>A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively&#xD;
      unimpaired participants at risk for or at the earliest stages of AD. The planned number of&#xD;
      participants for this study is approximately 1200 participants randomized in a 1:1 ratio to&#xD;
      receive either gantenerumab or placebo (600 participants randomized to gantenerumab and 600&#xD;
      participants randomized to placebo).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2022</start_date>
  <completion_date type="Anticipated">October 13, 2028</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Year 4 in Preclinical Alzheimer's Cognitive Composite-5 (PACC-5) Score</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from Randomization to Clinical Progression to Mild Cognitive Impairment (MCI) or Dementia due to AD</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Confirmed Clinical Progression</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Year 4 in the Amsterdam Instrumental Activities of Daily Living Questionnaire Short Version (A-IADL-Q-SV)</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Year 4 in the Cognitive Function Instrument Acute (CFIa)</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Year 4 in the Clinical Dementia Rating Sum of Boxes (CDR-SB)</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Drug Antibodies (ADAs)</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brain Amyloid Load Over Time in a Subset of Partcipants</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brain Tau Load Over Time in a Subset of Partcipants</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cerebrospinal Fluid (CSF) Abeta 1-42 Over Time in a Subset of Participants</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Abeta 1-40 Over Time in a Subset of Partcipants</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Neurofilament Light (NfL) Over Time in a Subset of Participants</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Phosphorylated Tau (pTau) Over Time in a Subset of Participants</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Total Tau (tTau) Over Time in a Subset of Participants</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Abeta 1-42 Over Time</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Abeta 1-40 Over Time</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood NfL Over Time</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood pTau Over Time</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Whole Brain Volume as Determined by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ventricle Volume as Determined by MRI</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hippocampal Volume as Determined by MRI</measure>
    <time_frame>Baseline up to Week 211</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Alzheimers Disease</condition>
  <arm_group>
    <arm_group_label>Gantenerumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gantenerumab will be administered as subcutaneous (SC) injection with gradual uptitration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered as SC injection with gradual uptitration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gantenerumab</intervention_name>
    <description>Gantenerumab will be administered as per the dosing schedule described in the Arm description.</description>
    <arm_group_label>Gantenerumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as per the dosing schedule described in the Arm description.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to comply with the study protocol and complete all aspects of the&#xD;
             study [including cognitive and functional assessments, physical and neurological&#xD;
             examinations, MRI, CSF collection, genotyping, and positron emission tomography (PET)&#xD;
             imaging].&#xD;
&#xD;
          -  Cognitively unimpaired with a screening clinical dementia rating global score (CDR-GS)&#xD;
             of 0, and Repeatable Battery for the Assessment of Neuropsychological Status Delayed&#xD;
             Memory Index (RBANS DMI) &gt;=80.&#xD;
&#xD;
          -  Evidence of cerebral amyloid accumulation.&#xD;
&#xD;
          -  Participants who have an available person (referred to as a &quot;study partner&quot;).&#xD;
&#xD;
          -  Fluent in the language of the tests used at the study site.&#xD;
&#xD;
          -  Adequate visual and auditory acuity, sufficient to perform neuropsychological testing&#xD;
             (eye glasses and hearing aids are permitted).&#xD;
&#xD;
          -  Agreed not to participate in other interventional research studies for the duration of&#xD;
             this trial.&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive methods that result in a failure rate&#xD;
             of &lt;1% per year during the treatment period and for at least 17 weeks after the final&#xD;
             dose of study treatment.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any evidence of an underlying neurological or neurodegenerative condition that may&#xD;
             lead to cognitive impairment other than AD.&#xD;
&#xD;
          -  Clinical diagnosis of mild cognitive impairment (MCI), prodromal AD, or any form of&#xD;
             dementia.&#xD;
&#xD;
          -  History or presence of intracranial or intracerebral vascular malformations, aneurysm,&#xD;
             subarachnoid hemorrhage, or intracerebral macrohemorrhage.&#xD;
&#xD;
          -  History or presence of posterior reversible encephalopathy syndrome.&#xD;
&#xD;
          -  History of ischemic stroke with clinical symptoms or an acute event that is consistent&#xD;
             with a transient ischemic attack within 12 months of screening.&#xD;
&#xD;
          -  History of severe, clinically significant (i.e., resulting in persistent neurologic&#xD;
             deficit or structural brain damage) central nervous system (CNS) trauma (e.g.,&#xD;
             cerebral contusion).&#xD;
&#xD;
          -  History or presence of intracranial mass lesion (e.g., glioma, meningioma) that could&#xD;
             potentially impair cognition or lead to progressive neurological deficits.&#xD;
&#xD;
          -  Infections that may affect brain function or a history of infections that resulted in&#xD;
             neurologic sequelae [e.g., human immunodeficiency virus (HIV), syphilis,&#xD;
             neuroborreliosis, and viral or bacterial meningitis and encephalitis].&#xD;
&#xD;
          -  History of major depression, schizophrenia, schizoaffective disorder, or bipolar&#xD;
             disorder.&#xD;
&#xD;
          -  At risk for suicide.&#xD;
&#xD;
          -  History of alcohol and/or substance abuse or dependence.&#xD;
&#xD;
          -  History or presence of clinically significant systemic vascular disease, atrial&#xD;
             fibrillation or heart failure.&#xD;
&#xD;
          -  Within the last year, experienced unstable or clinically significant cardiovascular&#xD;
             disease (e.g., myocardial infarction).&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  Chronic kidney disease, indicated by creatinine clearance &lt;30 mL/min.&#xD;
&#xD;
          -  Confirmed and unexplained impaired hepatic function.&#xD;
&#xD;
          -  History of, or are known to currently have an HIV infection, or hepatitis B or&#xD;
             hepatitis C virus infection that has not been adequately treated.&#xD;
&#xD;
          -  History or presence of systemic autoimmune disorders that may lead to progressive&#xD;
             neurological impairment with associated cognitive deficits.&#xD;
&#xD;
          -  Systemic immunosuppression or immunomodulation due to the continuing effects of&#xD;
             immunosuppressant or immunomodulating medications.&#xD;
&#xD;
          -  Current COVID-19 infection.&#xD;
&#xD;
          -  Evidence of folic acid or vitamin B-12 deficiency.&#xD;
&#xD;
          -  Any passive immunotherapy (Ig) or other long-acting biologic agent to prevent or&#xD;
             postpone cognitive decline within 1 year of screening.&#xD;
&#xD;
          -  Any other investigational treatment within 5 half-lives or 6 months (whichever is&#xD;
             longer) prior to screening.&#xD;
&#xD;
          -  Typical/Atypical anti-psychotic medications or neuroleptic medications.&#xD;
&#xD;
          -  Anticoagulation medications within 3 months of screening with no plans to initiate any&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Any previous treatment with cholinesterase inhibitors and N-methyl-D-aspartate&#xD;
             receptor antagonists are exclusionary at screening.&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             17 weeks after the final dose of gantenerumab.&#xD;
&#xD;
          -  Impaired coagulation.&#xD;
&#xD;
          -  Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric, human, or humanized antibodies or fusion proteins, including gantenerumab&#xD;
             and gantenerumab excipients.&#xD;
&#xD;
          -  Participants who reside in a skilled nursing facility such as a convalescent home or&#xD;
             long-term care facility.&#xD;
&#xD;
          -  Participants who require residence in such facilities during the study may continue in&#xD;
             the study and be followed for efficacy and safety, provided that they have a study&#xD;
             partner who meets the study partner requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WN42444 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Insitute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group, Inc</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JEM Research LLC</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Visionary Investigators Network - Neurology Aventura</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bradenton Research Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research, Inc.</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research; Center of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charter Research - Lady Lake/The Villages</name>
      <address>
        <city>Lady Lake</city>
        <state>Florida</state>
        <zip>32159</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinCloud, LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optimus U Corp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>K2 Medical Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research and Treatment Center</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johnnie B. Byrd Sr. Alzheimer's Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research and Treatment Center</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charter Research - Winter Park/Orlando</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Research &amp; Education</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Via Christi Research</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research, LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center; Dept of Neurological Sciences</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-8440</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cognitive and Research Center of New Jersey</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Memory Center</name>
      <address>
        <city>Matthews</city>
        <state>North Carolina</state>
        <zip>28105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University; College of Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Summit Research Network Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Senior Adults Specialty Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kerwin Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Re:Cognition Health</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NeuroSite</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1405CBA</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Kremer</name>
      <address>
        <city>Córdoba</city>
        <zip>X5004AOA</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Scherbovsky</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500AYB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Médicas Tucuman; REUMATHOLOGY</name>
      <address>
        <city>San Miguel</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KaRa Institute of Neurological Diseases</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2113</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Australian Alzheimer's Research Foundation</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okanagan Clinical Trials</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research-Halifax</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3S 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kawartha Centre - Redefining Healthy Aging</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9H 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto Memory Program</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alpha Recherche Clinique</name>
      <address>
        <city>Quebec</city>
        <zip>G3K 2P8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Santa Lucia IRCCS; Neurologia e Riabilitazione Neurologica</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00179</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Calibita Fatebenefratell;Neurologia</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele; U.O. di Neurologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA</name>
      <address>
        <city>Pozzilli</city>
        <state>Molise</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AO di Perugia - Ospedale S. Maria della Misericordia; Clinica Neurologica</name>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KLIMED</name>
      <address>
        <city>Białystok</city>
        <zip>15-704</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ Vitamed</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Senior Sp. Z O.O. Poradnia Psychogeriatryczna</name>
      <address>
        <city>Sopot</city>
        <zip>81-855</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Euromedis Sp. z o.o.</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ WCA</name>
      <address>
        <city>Wrocław</city>
        <zip>53-659</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron de Madrid; Servicio de Neurologia</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BARCELONABETA BRAIN RESEARCH CENTER (BBRC); FUNDACIÓN PASQUAL MARAGALL, Servicio de Neurologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación ACE; Servicio de Neurología</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío; Servicio de Neurología</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Academy University,Neuroscience and Physiology;Departmt of Psychiatry and Neurochemistry</name>
      <address>
        <city>Mölndal</city>
        <zip>431 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KAROLINSKA UNI HOSPITAL, HUDDINGE; Mottagning Kognitiv Forskning, M54</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Re-Cognition</name>
      <address>
        <city>Birmingham</city>
        <zip>B16 8QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Victoria Centre; Kingshill Research Centre</name>
      <address>
        <city>Swindon</city>
        <zip>SN3 6BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>January 25, 2022</study_first_submitted>
  <study_first_submitted_qc>February 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2022</study_first_posted>
  <last_update_submitted>November 4, 2022</last_update_submitted>
  <last_update_submitted_qc>November 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

